GlassScriptPhysician profile
Padmapriya Sivaraman
NPI 1699070391
$12,381.36
in general payments reported to CMS, 2019-2025
25 companies · $2,168 in 2025
The $2,168 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,905 · 2020: $618 · 2021: $311 · 2022: $1,239 · 2023: $2,316 · 2024: $2,825 · 2025: $2,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,186 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,185.71 |
| Education | $122.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,407.43 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,991.01 | 2019-2025 | Otezla, Enbrel, Evenity |
| Ucb, INC. | $1,670.40 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,056.25 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $954.06 | 2019-2025 | |
| Janssen Biotech, INC. | $784.83 | 2019-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $650.31 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $545.42 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $480.46 | 2019-2025 | Taltz |
| Astrazeneca Pharmaceuticals LP | $423.88 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $390.96 | 2019-2025 | Benlysta |
| Genzyme Corporation | $183.22 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.55 | 2024-2025 | Ofev, Cyltezo |
| Mallinckrodt Enterprises LLC | $113.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $90.05 | 2024-2025 | Strensiq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $79.44 | 2019-2023 | Actemra, Rituxan |
| Ani Pharmaceuticals, INC. | $75.68 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $67.18 | 2020-2025 | Acthar |
| Sandoz INC. | $65.56 | 2024 | Hyrimoz |
| Aurinia Pharma U.S., INC. | $55.71 | 2021-2025 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $55.00 | 2019 | |
| Radius Health, INC. | $42.63 | 2025 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $23.47 | 2024 | Truxima |
| Medexus Pharma, INC. | $16.43 | 2019 | |
| Merck Sharp & Dohme LLC | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padmapriya Sivaraman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.